Menu
ÚHKT

Impaktované publikace

[1]

Tiede, A.; Collins, P.; Knoebl, P.; Teitel, J.; Kessler, C.; Shima, M.; Di Minno, G.; D Oiron, R.; Salaj, P.; et al.

International recommendations on the diagnosis and treatment of acquired hemophilia

[rok vydání 2020, impact factor 7.116 ]

[2]

Kotlín, R.; Reicheltová, Z.; Malý, M.; Suttnar, J.; Sobotková, A.; Salaj, P.; Hirmerová, J.; Riedel, T.; Dyr, J.E.

Two cases of congenital dysfibrinogenemia associated with thrombosis : Fibrinogen Praha III and Fibrinogen Plzen

[rok vydání 2009, impact factor 4.451]

[3]

Kotlín, R.; Reicheltová, Z.; Sobotková, A.; Suttnar, J.; Salaj, P.; Pospíšilová, D.; Smejkal, P.; Chrastinová, L.; Dyr, J.E.

Three cases of abnormal fibrinogens : Šumperk (Bbeta His67Leu), Uničov (Bbeta Gly414Ser), and Brno (gammaArg275His)

[rok vydání 2008, impact factor 3.803]

[4]

Salaj, P.; Ovesna, P.; Penka, M.; Hedner, U.

Analyses of recombinant activated factor VII treatments from clinical practice for rapid bleeding and acute pain control in haemophilia patients with inhibitors

[rok vydání 2012, impact factor 3.170 ]

[5]

Salaj, P.; Penka, M.; Smejkal, P.; Geierova, V.; Ovesna, P.; Brabec, P.; Cetkovsky, P.; Kubes, R.; Mesterton, J.; Lindgren, P.

Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic

[rok vydání 2012, impact factor 3.133 ]

[6]

Salaj, P.; Geierová, V.; Ivanová, E.; Loužil, J.; Pohlreichová, V.; Hrachovinová, I.; Dulíček, P.

Identifying risk factors and optimizing standard of care for patients with acquired haemophilia A: results from a Czech patient cohort

[rok vydání 2020, impact factor 2.990 ]

[7]

Fuchs, O.; Provaznikova, D.; Kocova, M.; Kostecka, A.; Cvekova, P.; Neuwirtova, R.; Kobylka, P.; Cermak, J.; Brezinova, J.; Schwarz, J.; Markova, J.; Salaj, P.; Klamova, H.; Maaloufova, J.; Lemez, P.; Novakova, L.; Benesova, K.

CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin´s lymphoma

[rok vydání 2008, impact factor 2.749]

[8]

Provaznikova, D.; Houskova, K.; Radovska, A.; Salaj, P.; Hrachovinova, I.

Novel mutations associated with a discrepancy between one-stage and chromogenic FVIII activity assays

[rok vydání 2015, impact factor 2.673 ]

[9]

Křížová, P.; Mášová, L.; Suttnar, J.; Salaj, P.; Dyr, J.E.; Homola, J.; Pecka, M.

The influence of intrinsic coagulation pathway on blood platelets activation by oxidized cellulose

[rok vydání 2007, impact factor 2.612]

[10]

Shapiro, A.D.; Neufeld, E.J.; Blanchette, V.; Salaj, P.; Gut, R.Z.; Cooper, D.L.

Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg-1) rFVIIa doses across clinical trials and registries

[rok vydání 2014, impact factor 2.603 ]

[11]

Salaj, P.; Brabec, P.; Penka, M.; Pohlreichova, V.; Smejkal, P.; Cetkovsky, P.; Dusek, L.; Hedner, U.

Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors : analysis of HemoRec registry data from the Czech Republic

[rok vydání 2009, impact factor 2.505]

[12]

Santagostino, E.; Morfini, M.; Auerswald, G.K.; Benson, G.M.; Šalek, S.Z.; Lambert, T.; Salaj, P.; Jimenez-Yuste, V.; Ljung, R.C.R.

Paediatric haemophilia with inhibitors : existing management options, treatment gaps and unmet needs

[rok vydání 2009, impact factor 2.505]

[13]

Pan-Petesch, B.; Laguna, P.; Mital, A.; Stanley, J.; Torchet, M.F.; Salek, S.Z.; Salaj, P.

Single-dose (270 µg kg-1) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors : experience from seven European haemophilia centres

[rok vydání 2009, impact factor 2.505]

[14]

Salaj, P.; Gurlich, R.; Svorcova, V.; Markova, M.; Cetkovsky, P.

Prophylactic preparation and surgical extirpation of a very large abdominal blood cyst in a severe haemophilia A patient with inhibitors managed by rFVIIa

[rok vydání 2008, impact factor 2.505]

[15]

Kotlín, R.; Pastva, O.; Štikarová, J.; Hlaváčková, A.; Suttnar, J.; Chrastinová, L.; Riedel, T.; Salaj, P.; Dyr, J.E.

Two novel mutations in the fibrinogen gamma nodule

[rok vydání 2014, impact factor 2.447 ]

[16]

Salaj, P.; Kubes, R.; Cetkovsky, P.; Capova, I.; Penka, M.; Ovesna, P.; Mesterton, J.; Lindgren, P.

Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry

[rok vydání 2013, impact factor 2.447 ]

[17]

Kotlín, R.; Zichová, K.; Suttnar, J.; Reicheltová, Z.; Salaj, P.; Hrachovinová, I.; Dyr, J.E.

Congenital dysfibrinogenemia Aalpha Gly13Glu associated with bleeding during pregnancy.

[rok vydání 2010, impact factor 2.440]

[18]

Maly, M.; Hrachovinova, I.; Tomasov, P.; Salaj, P.; Hajek, P.; Veselka, J.

Patients with acute coronary syndromes have low tissue factor activity and microparticle count, but normal concentration of tissue factor antigen in platelet free plasma : a pilot study

[rok vydání 2008, impact factor 2.345]

[19]

Provaznikova, D.; Kumstyrova, T.; Kotlin, R.; Salaj, P.; Matoska, V.; Hrachovinova, I.; Rittich, S.

High-resolution melting analysis for detection of MYH9 mutations

[rok vydání 2008, impact factor 2.271]

[20]

Kotlín, R.; Sobotková, A.; Suttnar, J.; Salaj, P.; Walterová, L.; Riedel, T.; Reicheltová, Z.; Dyr, J.E.

A novel fibrinogen variant - Liberec : dysfibrinogenaemia associated with gamma Tyr262Cys substitution

[rok vydání 2008, impact factor 2.237]

Neimpaktované publikace

[1]

Salaj, P.

Ischemická choroba srdeční u diabetiků : epidemiologie, rizikové faktory, specifika diagnostických a terapeutických postupů

[rok vydání 2007]